Company: ANTX
Filing Date: 2025-04-10
Form Type: DEF 14A
Source: 0000950170-25-052852
Chunk: 15

Company: AN2 Therapeutics, Inc.
Filing Date: 2025-04-10
Form: DEF 14A
Chunk 15
---
 his support for NCATS, he also served as chair of the Cures Acceleration Network Review Board. From 2006 to 2018, Dr. Marks also served on the Scientific Advisory Board for the TB Alliance, a not-for-profit organization, including serving as chair. Since 2020, he has served on the Scientific Review Board for the Medicines for Malaria Venture (“MMV”), a not-for-profit organization, and has chaired

<div align='center'>7</div>

the Development Committee of MMV since 2022. Since 2009, he has served on the Scientific Advisory Committee for the Polio Antiviral Initiative. Since 2022, he has served as a consultant to Virodefense, a biotech firm focused on antivirals for poliovirus. From 2017 to 2021, Dr. Marks served as a member of the board of directors for WOAR, a not-for-profit rape crisis support center. Previously, from 1993 to 2017, Dr. Marks served in multiple roles at GlaxoSmithKline (now GSK), a publicly traded pharmaceutical company, including serving as Senior Vice President in Research & Development and as a member of the Pharmaceuticals R&D Leadership team. Dr. Marks received a B.S. in Chemistry from Auburn University and an M.D. from the University of South Alabama College of Medicine. He is Board Certified in Internal Medicine and Infectious Diseases. We believe that Dr. Marks’ over 30 years of experience in the field of infectious diseases and as a senior executive in the pharmaceutical industry makes him an appropriate member of our Board.

Patricia (Patty) Martinhas served as a member of our Board since April 2021. From July 2019 through March 2023, Ms. Martin servedas the President and Chief Executive Officer of BioCrossroads, a not-for-profit organization that supports and promotes the life sciences industry in the state of Indiana, and served as the Managing Partner of BC Initiative, Inc., a company that supports seed fund investing in life sciences. From June 1991 to June 2017, Ms. Martin held multiple positions at Eli Lilly and Company (“Eli Lilly”), a publicly traded pharmaceutical company, including Chief Operations Officer of Lilly Diabetes, Chief Diversity Officer and Chief Alliance Officer. Ms. Martin currently also serves as a member of the board of directors of Leap Therapeutics, Inc., a Nasdaq listed immuno-oncology company, and several private companies, including Indiana